OOIR: Observatory of International Research

Papers

(The TQCC of Nature Reviews Cancer is 31. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Computing brain metastasis impact	762
Fructose takes a detour to feed cancer	538
Combining spatial transcriptomics and AI to enhance brain tumour diagnosis	521
INVADEseq to study the intratumoural microbiota at host single-cell resolution	505
Exploiting metabolic cell death for cancer therapy	472
Oncofetal reprogramming in tumour development and progression	429
Implementing practice-changing progress for managing cancer of unknown primary	429
Combinatorial strategies to target RAS-driven cancers	395
Convergent inducers and effectors of T cell paralysis in the tumour microenvironment	356
Emerging strategies to investigate the biology of early cancer	328
Claudin proteins as emerging therapeutic targets for solid tumours	320
Mapping the prostate cell family tree	317
Fighting cancer with fat	305
Reply to ‘Heterogeneity of TP53 mutations necessitates differentiation with p53-rescue therapies’	286
3D chromatin architecture as a predictor of somatic mutations in cancer genomes	286
Connie J. Eaves (1944–2024)	285
Avoiding cancer through collective behaviour	283
How medical anthropology can contribute to cancer research	271
Author Correction: Fighting rare cancers: lessons from fibrolamellar hepatocellular carcinoma	266
The recruitment of metastasis-associated monocytes	264
The evolution of cancer and ageing: a history of constraint	263
Tertiary lymphoid structures as hubs of antitumour immunity	253
Translating premalignant biology to accelerate non-small-cell lung cancer interception	250
Epithelial and stromal co-evolution and complicity in pancreatic cancer	233
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies	232

Beyond genetics: driving cancer with the tumour microenvironment behind the wheel	230
Nanoreceptors take down mutant p53	225
Impersonating neurons	218
Tumour EVPs disrupt liver function	213
Defining a ‘cells to society’ research framework for appendiceal tumours	205
AACR 2025	203
Measuring HLA disruption using MHC Hammer	200
No mutation, tumour initiation	198
Persistence is key	190
Thelpers? More like Ttroublemakers	189
Gut microbes produce novel genotoxic metabolites	181
Dendritic cells rise and shine	179
Removing barriers to address sex differences in anticancer drug toxicity	177
3D bioprinted cancer models: from basic biology to drug development	174
Moonlighting functions of glucose metabolic enzymes and metabolites in cancer	172
Rethinking ovarian cancer III: the past decade and future directions	169
How chemokines organize the tumour microenvironment	167
Bone voyage: immune crosstalk sets sail	164
B-ring sterols to the rescue	161
Visualizing intratumoural heterogeneity with EpicMIBI	148
Double trouble for the tumour glycocode	145
Identifying spatial cellular structures with SPACE-GM	140
In-depth organoid profiling of pancreatic cancer	134
Beyond oncogenesis: the unexplored benefits of viruses in cancer immunity	132
Linking cell mechanical memory and cancer metastasis	132
Context-dependent synthetic lethality — an emerging precision therapeutic approach	131
Imaging the hallmarks of cancer	125
Environmental endocrine disruptors: rethinking the origins of early-onset ER+ breast cancer	118
Enhancer and metabolic rewiring by KMT2C–COMPASS or KMT2D–COMPASS family loss in cancer creates druggable vulnerabilities	112
The path to leptomeningeal metastasis	110
Metabolic interplays between the tumour and the host shape the tumour macroenvironment	109
Opportunities and challenges of targeting cGAS–STING in cancer	103
The immune microenvironment of colorectal cancer	102
Regulatory T cells in the tumour microenvironment	101
Dynamics and specificities of T cells in cancer immunotherapy	100
Leveraging the replication stress response to optimize cancer therapy	100
Understanding and addressing race disparities in childhood cancer outcomes	99
Encoding spatial tumour dynamics with Starfysh	94
Race influences the tumour microbiome	90
Deciphering the cancer genome and epigenome	90
ER stress sparks nerve pain	89
Re-routing IgE for cancer therapy	86
Being in the zone	86
Polygenic scores in cancer	85
Beat it!	83
Advancing AI for multi-omics and clinical data integration in basic and translational cancer research	82
Stem cells as an essential mediator of the exercise–tumorigenesis link	80
Detection of cytokine-responsive cells using CyCLoPs	79
RNA splicing dysregulation and the hallmarks of cancer	78
Acetyl-CoA metabolism in cancer	77

Targeted protein degradation for cancer therapy	76
Cancer nanomedicine	75
Expanding the utility of precision oncology knowledge bases	74
NOTUM-mediated stem cell competition in CRC	74
Local CAR manufacturing	74
Tamoxifen takes the wheel	72
Right ON target: a new RAS-GTP inhibitor	71
When the time is right	71
Chromothripsis in cancer	69
Decoding cancer across scales with metabolomics	66
Defining precancer: a grand challenge for the cancer community	63
GABA takes the edge off anti-tumour immunity	63
Androgen receptor signalling in non-prostatic malignancies: challenges and opportunities	62
Prime editing GEMMs to model cancer mutations	59
Integrative medicine in oncology: redefining the standard of care	58
Tertiary lymphoid structures in anticancer immunity	56
In vivo labelling system to study cell neighbourhoods	53
Judith Campisi (1948–2024)	50
Revealing genomic secrets of archival FFPE samples	50
New pathogen on the block	49
Cancer risk in children with congenital anomalies	48
Melanomagenesis antagonizes stem cell ageing	48
Inferring cancer metabolism from gene-expression data	45
Regulation of immune checkpoint molecules in cancer immune evasion and therapy	44
N6-Methyladenosine: an RNA modification as a central regulator of cancer	43
Recent advances in therapeutic cancer vaccines	43
Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart	43
The present and future of the Cancer Dependency Map	42
Patient-derived organoids unveil sarcoma vulnerabilities	41
Carcinogenesis at single-cell resolution	41
Focusing on the complex and dynamic interplay between ageing and cancer	41
Global post-mortem tissue donation programmes to accelerate cancer research	41
Transfer RNAs as dynamic and critical regulators of cancer progression	40
Epigenomic heterogeneity as a source of tumour evolution	38
A timeline of tumour-associated macrophage biology	38
Radiation as an immune modulator: mechanisms and implications for combination with immunotherapy	38
Traject3d for studying 3D cellular heterogeneity	36
Author Correction: Integrative medicine in oncology: redefining the standard of care	35
Guardrails for the use of generalist AI in cancer care	35
Digitally enhanced Raman spectroscopy	35
Harnessing the influenza virus to fight cancer	32
We cannot ignore the cancer risks of wildfires	31